Literature DB >> 12089275

Detection of Epstein-Barr virus genomes in peripheral blood B cells from solid-organ transplant recipients by fluorescence in situ hybridization.

Camille Rose1, Michael Green, Steven Webber, Lawrence Kingsley, Roger Day, Simon Watkins, Jorges Reyes, David Rowe.   

Abstract

Resolution of Epstein-Barr Virus (EBV) infection in pediatric solid-organ transplant recipients often leads to an asymptomatic carrier state characterized by a persistently elevated circulating EBV load that is 2 to 4 orders of magnitude greater than the load typical of healthy latently infected individuals. Elevated EBV loads in immunosuppressed individuals are associated with an increased risk for development of posttransplant lymphoproliferative disease. We have performed fluorescence in situ hybridization (FISH) studies with peripheral blood B cells from carriers of persistent EBV loads in order to directly quantitate the number of EBV genomes per infected cell. Patients were assigned to two groups on the basis of the level of the persistent load (low-load carriers, 8 to 200 genomes/10(5) peripheral blood lymphocytes; high-load carriers, >200 genomes/10(5) peripheral blood lymphocytes). FISH analysis revealed that the low-load carriers predominantly had circulating virus-infected cells harboring one or two genome copies/cell. High-load carriers also had cells harboring one or two genome copies/cell; in addition, however, they carried a distinct population of cells with high numbers of viral genome copies. The increased viral loads correlated with an increase in the frequency of cells containing high numbers of viral genomes. We conclude that low-load carriers possess EBV-infected cells that are in a state similar to normal latency, whereas high-load carriers possess two populations of virus-positive B cells, one of which carries an increased number of viral genomes per cell and is not typical of normal latency.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12089275      PMCID: PMC120580          DOI: 10.1128/JCM.40.7.2533-2544.2002

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  49 in total

1.  Post-transplantation lymphoproliferative disorders: advances in diagnosis, prevention and management in children.

Authors: 
Journal:  Prog Pediatr Cardiol       Date:  2000-06-01

2.  Predictive value of Epstein-Barr virus genome copy number and BZLF1 expression in blood lymphocytes of transplant recipients at risk for lymphoproliferative disease.

Authors:  P Vajro; S Lucariello; F Migliaro; E Sokal; B Gridelli; A Vegnente; R Iorio; F Smets; I Quinto; G Scala
Journal:  J Infect Dis       Date:  2000-06-05       Impact factor: 5.226

3.  EBV persistence in memory B cells in vivo.

Authors:  G J Babcock; L L Decker; M Volk; D A Thorley-Lawson
Journal:  Immunity       Date:  1998-09       Impact factor: 31.745

4.  Is EBV persistence in vivo a model for B cell homeostasis?

Authors:  G Khan; E M Miyashita; B Yang; G J Babcock; D A Thorley-Lawson
Journal:  Immunity       Date:  1996-08       Impact factor: 31.745

Review 5.  Human cytotoxic T lymphocyte responses to Epstein-Barr virus infection.

Authors:  A B Rickinson; D J Moss
Journal:  Annu Rev Immunol       Date:  1997       Impact factor: 28.527

6.  Initiation of latent DNA replication in the Epstein-Barr virus genome can occur at sites other than the genetically defined origin.

Authors:  R D Little; C L Schildkraut
Journal:  Mol Cell Biol       Date:  1995-05       Impact factor: 4.272

7.  Characterization of Epstein-Barr virus-infected B cells in patients with posttransplantation lymphoproliferative disease: disappearance after rituximab therapy does not predict clinical response.

Authors:  J Yang; Q Tao; I W Flinn; P G Murray; L E Post; H Ma; S Piantadosi; M A Caligiuri; R F Ambinder
Journal:  Blood       Date:  2000-12-15       Impact factor: 22.113

8.  Epstein-Barr virus-associated post-transplant lympho-proliferative disease of donor origin in liver transplant recipients.

Authors:  M Strazzabosco; B Corneo; R M Iemmolo; C Menin; G Gerunda; L Bonaldi; R Merenda; D Neri; A Poletti; M Montagna; A Del Mistro; A M Faccioli; E D'Andrea
Journal:  J Hepatol       Date:  1997-04       Impact factor: 25.083

9.  Serial measurement of Epstein-Barr viral load in peripheral blood in pediatric liver transplant recipients during treatment for posttransplant lymphoproliferative disease.

Authors:  M Green; T V Cacciarelli; G V Mazariegos; L Sigurdsson; L Qu; D T Rowe; J Reyes
Journal:  Transplantation       Date:  1998-12-27       Impact factor: 4.939

10.  Incidence and outcome of primary Epstein-Barr virus infection and lymphoproliferative disease in pediatric heart transplant recipients.

Authors:  S D Zangwill; D T Hsu; M R Kichuk; J H Garvin; C J Stolar; J Haddad; S Stylianos; R E Michler; A Chadburn; D M Knowles; L J Addonizio
Journal:  J Heart Lung Transplant       Date:  1998-12       Impact factor: 10.247

View more
  6 in total

1.  Surface immunoglobulin-deficient Epstein-Barr virus-infected B cells in the peripheral blood of pediatric solid-organ transplant recipients.

Authors:  Elizabeth Schauer; Steven Webber; Michael Green; David Rowe
Journal:  J Clin Microbiol       Date:  2004-12       Impact factor: 5.948

2.  Detection of EBV genomes in plasmablasts/plasma cells and non-B cells in the blood of most patients with EBV lymphoproliferative disorders by using Immuno-FISH.

Authors:  Sara Calattini; Irini Sereti; Philip Scheinberg; Hiroshi Kimura; Richard W Childs; Jeffrey I Cohen
Journal:  Blood       Date:  2010-08-10       Impact factor: 22.113

3.  Infection and persistence of rhesus monkey rhadinovirus in immortalized B-cell lines.

Authors:  John P Bilello; Sabine M Lang; Fred Wang; Jon C Aster; Ronald C Desrosiers
Journal:  J Virol       Date:  2006-04       Impact factor: 5.103

4.  Memory B-cell reconstitution following allogeneic hematopoietic stem cell transplantation is an EBV-associated transformation event.

Authors:  David M Burns; Rose Tierney; Claire Shannon-Lowe; Jo Croudace; Charlotte Inman; Ben Abbotts; Sandeep Nagra; Christopher P Fox; Sridhar Chaganti; Charles F Craddock; Paul Moss; Alan B Rickinson; Martin Rowe; Andrew I Bell
Journal:  Blood       Date:  2015-10-08       Impact factor: 25.476

5.  Aspirin Inhibits Natural Killer/T-Cell Lymphoma by Modulation of VEGF Expression and Mitochondrial Function.

Authors:  Hongyu Zhang; Jianping Lu; Yun Jiao; Qi Chen; Min Li; Zichen Wang; Zhendong Yu; Xiaodong Huang; Athena Yao; Qiong Gao; Weiguo Xie; Ling Li; Paul Yao
Journal:  Front Oncol       Date:  2019-01-14       Impact factor: 6.244

6.  Combination of betulinic acid and chidamide synergistically inhibits Epstein-Barr virus replication through over-generation of reactive oxygen species.

Authors:  Haibing Yu; Hongyu Zhang; Zhigang Chu; Qiongfang Ruan; Xueru Chen; Danli Kong; Xiaodong Huang; Huawen Li; Huanwen Tang; Hongjin Wu; Yifei Wang; Weiguo Xie; Yuanling Ding; Paul Yao
Journal:  Oncotarget       Date:  2017-06-27
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.